Heart Failure

Researchers in Italy are developing “smart,” photo-responsive materials they hope will replicate the mechanical properties of a human heart in an artificial format, Cosmos Magazine reported July 12.

The Center to Advance Palliative Care suggests steps cardiologists can take to ensure ongoing identification and management of remediable sources of suffering and distress in heart failure patients.

The combination heart failure drug sacubitril/valsartan is well-covered under Medicare Part D plans, according to a recent analysis, but patient access to the medication remains limited by steep out-of-pocket costs than can exceed $1,600 annually.

Only half of the world’s countries offer cardiac rehabilitation programs, according to a recent survey, leaving some 18 million heart patients across the globe without access to therapy that could vastly improve their prognosis and quality of life.

A large-scale study of people living with HIV has linked the immune deficiency to an increased risk of CVD, in particular heart failure and stroke.

Heart patients of a lower socioeconomic status are far more likely to participate in cardiac rehabilitation if they receive financial incentives to attend sessions, according to a study published in the July 1 edition of JACC: Heart Failure.

The FDA on June 26 granted Boehringer Ingelheim and Eli Lilly and Company’s drug empagliflozin Fast Track designation for the treatment of chronic heart failure, the companies announced.

One in five Americans are able to recognize the symptoms of heart failure, according to a new survey from Abbott—a troublesome finding considering the same research puts the average individual just four degrees of separation from HF.

Researchers at Imperial College London have developed a sew-on heart patch that leverages stem cells to support and repair heart muscle after a heart attack—something that could dramatically lower MI survivors’ risk of future heart failure.

Loneliness, above all else, was an independent predictor of whether patients stuck to their doctors’ guidelines.

A recent analysis of the COAPT trial, published this spring in the Journal of the American College of Cardiology, suggests patients with symptomatic heart failure (HF) and secondary mitral regurgitation (MR) might see better mental and physical outcomes if they’re treated with edge-to-edge transcatheter mitral valve repair (TMVR) in lieu of standard therapy.

The risk of peripartum cardiomyopathy (PPCM) is up to five times higher in mothers who undergo common fertility treatments like intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF), according to data presented at Heart Failure 2019 in Athens.